• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

房水单核细胞趋化蛋白-1 预测接受玻璃体内注射贝伐单抗和玻璃体切除术的增生性糖尿病性视网膜病变的长期视力预后。

Aqueous humor monocyte chemoattractant protein-1 predicted long-term visual outcome of proliferative diabetic retinopathy undergone intravitreal injection of bevacizumab and vitrectomy.

机构信息

Department of Ophthalmology, 1st affiliated hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.

Department of Ophthalmology, Xi'an No. 1 hospital, Xi'an, China.

出版信息

PLoS One. 2021 Mar 5;16(3):e0248235. doi: 10.1371/journal.pone.0248235. eCollection 2021.

DOI:10.1371/journal.pone.0248235
PMID:33667285
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7935263/
Abstract

PURPOSE

We aim to investigate the risk factors associated with the prognosis of proliferative diabetic retinopathy (PDR) after a sequential treatment of intravitreal injection of bevacizumab (IVB) and pars plana vitrectomy (PPV).

METHODS

In this cohort study, 63 eyes from 55 patients (21 females) diagnosed with PDR, who needed PPV for non-clearing vitreous hemorrhage or fibrovascular membrane proliferation were enrolled. All the eyes underwent IVB followed by PPV. Anterior chamber tap was performed at the beginning of both procedures to evaluate the concentration of vascular endothelial growth factor (VEGF), interleukin (IL)-6, IL-8, and monocyte chemoattractant protein (MCP)-1.

RESULTS

Forty-seven patients (54 eyes) were followed over six months, averaging 12±5 (6-19) months. The concentration of VEGF significantly decreased after IVB (P<0.001), while other cytokines did not change significantly. The aqueous humor level of IL-8 after IVB (R = 0.378, P = 0.033), MCP-1 before (R = 0.368, P = 0.021) and after (R = 0.368, P = 0.038) IVB, and combined phacoemulsification (R = 0.293, P = 0.032) was correlated with the logMAR visual acuity at the last follow-up. Multivariate analysis showed that MCP-1 was the predictor for a worse visual outcome (B = 0.108, 95% CI 0.013-0.202; P = 0.027).

CONCLUSIONS

MCP-1 was a predictor for the unfavorable visual outcome of PDR after IVB pretreatment and PPV.

摘要

目的

我们旨在研究玻璃体切割术(PPV)前序治疗中玻璃体内注射贝伐单抗(IVB)和经平坦部玻璃体切除术(PPV)与增殖性糖尿病性视网膜病变(PDR)预后相关的危险因素。

方法

在这项队列研究中,纳入了 55 名患者(21 名女性)的 63 只眼,这些患者被诊断患有 PDR,需要 PPV 以清除不透明的玻璃体积血或纤维血管膜增生。所有患者均接受 IVB 治疗,然后行 PPV。在这两种手术开始时进行前房穿刺,以评估血管内皮生长因子(VEGF)、白细胞介素(IL)-6、IL-8 和单核细胞趋化蛋白(MCP)-1 的浓度。

结果

47 名患者(54 只眼)接受了 6 个月的随访,平均随访时间为 12±5(6-19)个月。IVB 后 VEGF 浓度显著降低(P<0.001),而其他细胞因子浓度没有显著变化。IVB 后 IL-8 的房水水平(R = 0.378,P = 0.033)、IVB 前(R = 0.368,P = 0.021)和 IVB 后(R = 0.368,P = 0.038)和联合超声乳化(R = 0.293,P = 0.032)与最后一次随访时的 logMAR 视力相关。多变量分析显示,MCP-1 是视觉结果较差的预测因子(B = 0.108,95%CI 0.013-0.202;P = 0.027)。

结论

MCP-1 是 IVB 预处理和 PPV 后 PDR 视力不良的预测因子。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b698/7935263/4cd5f248f4bd/pone.0248235.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b698/7935263/4cd5f248f4bd/pone.0248235.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b698/7935263/4cd5f248f4bd/pone.0248235.g001.jpg

相似文献

1
Aqueous humor monocyte chemoattractant protein-1 predicted long-term visual outcome of proliferative diabetic retinopathy undergone intravitreal injection of bevacizumab and vitrectomy.房水单核细胞趋化蛋白-1 预测接受玻璃体内注射贝伐单抗和玻璃体切除术的增生性糖尿病性视网膜病变的长期视力预后。
PLoS One. 2021 Mar 5;16(3):e0248235. doi: 10.1371/journal.pone.0248235. eCollection 2021.
2
Preoperative Timing of Intravitreal Bevacizumab Injection for Proliferative Diabetic Retinopathy Patients.增殖性糖尿病视网膜病变患者玻璃体内注射贝伐单抗的术前时机
Ophthalmic Res. 2018;60(4):250-257. doi: 10.1159/000493640. Epub 2018 Oct 31.
3
Six-month visual outcome after pars plana vitrectomy in proliferative diabetic retinopathy with or without a single preoperative injection of intravitreal bevacizumab.增生性糖尿病视网膜病变患者行玻璃体切割术,术前单次玻璃体腔内注射或未注射贝伐单抗后的6个月视力转归
Int Ophthalmol. 2012 Apr;32(2):135-44. doi: 10.1007/s10792-012-9541-5. Epub 2012 Mar 27.
4
Microincision vitrectomy surgery and intravitreal bevacizumab as a surgical adjunct to treat diabetic traction retinal detachment.微创玻璃体切除术联合玻璃体内注射贝伐单抗作为手术辅助治疗糖尿病性牵拉性视网膜脱离。
Ophthalmology. 2009 May;116(5):927-38. doi: 10.1016/j.ophtha.2008.11.005. Epub 2009 Mar 9.
5
Alterations in the intraocular cytokine milieu after intravitreal bevacizumab.玻璃体内注射贝伐单抗后眼内细胞因子环境的改变。
Invest Ophthalmol Vis Sci. 2010 May;51(5):2388-92. doi: 10.1167/iovs.09-4065. Epub 2009 Dec 10.
6
Intravitreal bevacizumab for prevention of early postvitrectomy hemorrhage in diabetic patients: a randomized clinical trial.玻璃体内注射贝伐单抗预防糖尿病患者玻璃体切除术后早期出血:一项随机临床试验。
Ophthalmology. 2009 Oct;116(10):1943-8. doi: 10.1016/j.ophtha.2009.07.001. Epub 2009 Aug 21.
7
Intraocular pharmacokinetics of anti-vascular endothelial growth factor agents by intraoperative subretinal versus intravitreal injection in silicone oil-filled eyes of proliferative diabetic retinopathy: a randomized controlled pilot study.增生型糖尿病视网膜病变硅油填充眼玻璃体内与视网膜下注射抗血管内皮生长因子药物的眼内药代动力学:一项随机对照初步研究。
Acta Ophthalmol. 2020 Nov;98(7):e795-e800. doi: 10.1111/aos.14386. Epub 2020 Feb 29.
8
Elevated Activating Transcription Factor 4 and Glucose-Regulated 78 Kda Protein Levels Correlate with Inflammatory Cytokines in the Aqueous Humor and Vitreous of Proliferative Diabetic Retinopathy.增殖性糖尿病视网膜病变患者房水和玻璃体内活化转录因子4及葡萄糖调节蛋白78 kDa水平升高与炎性细胞因子相关。
Curr Eye Res. 2017 Aug;42(8):1202-1208. doi: 10.1080/02713683.2017.1297998. Epub 2017 May 12.
9
Comparison of before versus after intravitreal bevacizumab injection, growth factor levels and fibrotic markers in vitreous samples from patients with proliferative diabetic retinopathy.增殖性糖尿病视网膜病变患者玻璃体内注射贝伐单抗前后玻璃体液样本中生长因子水平及纤维化标志物的比较。
Graefes Arch Clin Exp Ophthalmol. 2022 Jun;260(6):1899-1906. doi: 10.1007/s00417-021-05515-3. Epub 2022 Jan 14.
10
The effect of adjunctive intravitreal bevacizumab for preventing postvitrectomy hemorrhage in proliferative diabetic retinopathy.辅助玻璃体内注射贝伐单抗预防增生性糖尿病视网膜病变玻璃体切割术后出血的效果。
Ophthalmology. 2011 Nov;118(11):2218-26. doi: 10.1016/j.ophtha.2011.03.036. Epub 2011 Jul 2.

引用本文的文献

1
Liquid Biopsy Combined with Multi-Omics Approaches in Diagnosis, Management, and Progression of Diabetic Retinopathy.液体活检联合多组学方法在糖尿病视网膜病变的诊断、管理及病情进展中的应用
Biomedicines. 2025 May 26;13(6):1306. doi: 10.3390/biomedicines13061306.
2
Clinical Features and Vitreous Biomarkers of Early-Onset Type 2 Diabetes Mellitus Complicated with Proliferative Diabetic Retinopathy.早发型2型糖尿病合并增殖性糖尿病视网膜病变的临床特征及玻璃体生物标志物
Diabetes Metab Syndr Obes. 2022 Apr 26;15:1293-1303. doi: 10.2147/DMSO.S362074. eCollection 2022.

本文引用的文献

1
Correlation of Aqueous, Vitreous, and Plasma Cytokine Levels in Patients With Proliferative Diabetic Retinopathy.增生型糖尿病视网膜病变患者房水、玻璃体和血浆细胞因子水平的相关性。
Invest Ophthalmol Vis Sci. 2020 Feb 7;61(2):26. doi: 10.1167/iovs.61.2.26.
2
Aqueous humour cytokine changes during a loading phase of intravitreal ranibizumab or dexamethasone implant in diabetic macular oedema.在糖尿病黄斑水肿的玻璃体腔内雷珠单抗或地塞米松植入物负荷期,房水细胞因子发生变化。
Acta Ophthalmol. 2020 Jun;98(4):e407-e415. doi: 10.1111/aos.14297. Epub 2019 Nov 17.
3
Anatomic Response to Intravitreal Dexamethasone Implant and Baseline Aqueous Humor Cytokine Levels in Diabetic Macular Edema.
玻璃体内注射地塞米松植入物与糖尿病性黄斑水肿患者基础房水细胞因子水平的解剖学反应。
Invest Ophthalmol Vis Sci. 2019 Apr 1;60(5):1336-1343. doi: 10.1167/iovs.18-26215.
4
Monocyte chemoattractant protein-1 (MCP-1/CCL2) in diabetic retinopathy: latest evidence and clinical considerations.糖尿病视网膜病变中的单核细胞趋化蛋白-1(MCP-1/CCL2):最新证据与临床考量
J Cell Commun Signal. 2019 Dec;13(4):451-462. doi: 10.1007/s12079-018-00500-8. Epub 2019 Jan 3.
5
Cost Evaluation of Early Vitrectomy versus Panretinal Photocoagulation and Intravitreal Ranibizumab for Proliferative Diabetic Retinopathy.增生型糖尿病视网膜病变行早期玻璃体切割术与全视网膜光凝及玻璃体内雷珠单抗治疗的成本评估
Ophthalmology. 2018 Sep;125(9):1393-1400. doi: 10.1016/j.ophtha.2018.02.038. Epub 2018 Mar 29.
6
Antivascular endothelial growth factor agents pretreatment before vitrectomy for complicated proliferative diabetic retinopathy: a meta-analysis of randomised controlled trials.抗血管内皮生长因子药物预处理对复杂增殖性糖尿病视网膜病变玻璃体切割术的影响:一项随机对照试验的荟萃分析。
Br J Ophthalmol. 2018 Aug;102(8):1077-1085. doi: 10.1136/bjophthalmol-2017-311344. Epub 2017 Dec 15.
7
Differential association of elevated inflammatory cytokines with postoperative fibrous proliferation and neovascularization after unsuccessful vitrectomy in eyes with proliferative diabetic retinopathy.增殖性糖尿病视网膜病变患者玻璃体切割术失败后,炎症细胞因子升高与术后纤维增生和新生血管形成的差异关联。
Clin Ophthalmol. 2017 Sep 19;11:1697-1705. doi: 10.2147/OPTH.S141821. eCollection 2017.
8
Preoperative Bevacizumab Administration in Proliferative Diabetic Retinopathy Patients Undergoing Vitrectomy: A Randomized and Controlled Trial Comparing Interval Variation.接受玻璃体切除术的增殖性糖尿病视网膜病变患者术前使用贝伐单抗:一项比较间隔差异的随机对照试验
Am J Ophthalmol. 2017 Nov;183:1-10. doi: 10.1016/j.ajo.2017.08.013. Epub 2017 Aug 30.
9
Association of increased levels of MCP-1 and cathepsin-D in young onset type 2 diabetes patients (T2DM-Y) with severity of diabetic retinopathy.年轻发病的2型糖尿病患者(T2DM-Y)中MCP-1和组织蛋白酶D水平升高与糖尿病视网膜病变严重程度的关联。
J Diabetes Complications. 2017 May;31(5):804-809. doi: 10.1016/j.jdiacomp.2017.02.017. Epub 2017 Mar 10.
10
Level of Vascular Endothelial Growth Factor in the Vitreous Fluid of Proliferative Diabetic Retinopathy Patients and Prognosis after Vitrectomy.增殖性糖尿病视网膜病变患者玻璃体液中血管内皮生长因子水平及玻璃体切除术后的预后
Ophthalmologica. 2016;236(3):133-138. doi: 10.1159/000449261. Epub 2016 Oct 29.